{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:04:20Z","timestamp":1789610660013,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16408-1","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:18:43Z","timestamp":1782814723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy of postoperative adjuvant chemoradiotherapy versus no chemoradiotherapy in the treatment of pancreatic adenocarcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Bixin","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiliang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"1","key":"16408_CR1","first-page":"e70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NK, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"16408_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.6004\/jnccn.2019.0014","volume":"17","author":"MA Tempero","year":"2019","unstructured":"Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, et al. Pancreatic adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):202\u201310.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"16408_CR3","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"16408_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/SLA.0000000000003242","volume":"273","author":"SK Kamarajah","year":"2021","unstructured":"Kamarajah SK, Sonnenday CJ, Cho CS, Frankel TL, Bednar F, Lawrence TS, et al. Association of adjuvant radiotherapy with survival after margin-negative resection of pancreatic ductal adenocarcinoma: a propensity-matched National Cancer Database (NCDB) Analysis. Ann Surg. 2021;273(3):587\u201394.","journal-title":"Ann Surg"},{"issue":"5","key":"16408_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.surg.2017.09.022","volume":"163","author":"NR Suss","year":"2018","unstructured":"Suss NR, Talamonti MS, Bryan DS, Wang CH, Kuchta KM, Stocker SJ, et al. Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? Surgery. 2018;163(5):1047\u201352.","journal-title":"Surgery"},{"issue":"23","key":"16408_CR6","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1002\/cncr.29652","volume":"121","author":"CE Rutter","year":"2015","unstructured":"Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the National Cancer Data Base. Cancer. 2015;121(23):4141\u20139.","journal-title":"Cancer"},{"issue":"6","key":"16408_CR7","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.surg.2016.07.033","volume":"160","author":"O Kantor","year":"2016","unstructured":"Kantor O, Talamonti MS, Lutfi W, Wang CH, Winchester DJ, Marsh R, et al. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma. Surgery. 2016;160(6):1466\u201376.","journal-title":"Surgery"},{"key":"16408_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12957-015-0560-3","volume":"13","author":"D Habermehl","year":"2015","unstructured":"Habermehl D, Brecht IC, Bergmann F, Rieken S, Werner J, Buchler MW, et al. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World J Surg Oncol. 2015;13:149.","journal-title":"World J Surg Oncol"},{"issue":"12","key":"16408_CR9","doi-asserted-by":"publisher","first-page":"e83138","DOI":"10.1371\/journal.pone.0083138","volume":"8","author":"N Panic","year":"2013","unstructured":"Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS ONE. 2013;8(12):e83138.","journal-title":"PLoS ONE"},{"issue":"9","key":"16408_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"7414","key":"16408_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"3","key":"16408_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785\u201394.","journal-title":"Biometrics"},{"issue":"12","key":"16408_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200\u201310.","journal-title":"N Engl J Med"},{"issue":"6","key":"16408_CR14","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/cam4.1479","volume":"7","author":"MC Hsieh","year":"2018","unstructured":"Hsieh MC, Chang WW, Yu HH, Lu CY, Chang CL, Chow JM, et al. Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy. Cancer Med. 2018;7(6):2328\u201338.","journal-title":"Cancer Med"},{"issue":"5","key":"16408_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jamcollsurg.2008.12.020","volume":"208","author":"NB Merchant","year":"2009","unstructured":"Merchant NB, Rymer J, Koehler EA, Ayers GD, Castellanos J, Kooby DA, et al. Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg. 2009;208(5):829\u201338. discussion 838\u2013841.","journal-title":"J Am Coll Surg"},{"issue":"21","key":"16408_CR16","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1200\/JCO.2007.15.8782","volume":"26","author":"MM Corsini","year":"2008","unstructured":"Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975\u20132005). J Clin Oncol. 2008;26(21):3511\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16408_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11605-015-2951-8","volume":"20","author":"SW de Geus","year":"2016","unstructured":"de Geus SW, Bliss LA, Eskander MF, Ng SC, Vahrmeijer AL, Mahadevan A, et al. A tale of two cities: reconsidering adjuvant radiation in pancreatic cancer care. J Gastrointest Surg. 2016;20(1):85\u201392. discussion 92.","journal-title":"J Gastrointest Surg"},{"issue":"21","key":"16408_CR18","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2007.15.8469","volume":"26","author":"JM Herman","year":"2008","unstructured":"Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503\u201310.","journal-title":"J Clin Oncol"},{"issue":"4","key":"16408_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1245\/s10434-009-0743-7","volume":"17","author":"CC Hsu","year":"2010","unstructured":"Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"16408_CR20","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.ijrobp.2010.04.003","volume":"80","author":"DP Horowitz","year":"2011","unstructured":"Horowitz DP, Hsu CC, Wang J, Makary MA, Winter JM, Robinson R, et al. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2011;80(5):1391\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"29","key":"16408_CR21","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1200\/JCO.2010.30.3446","volume":"28","author":"JL Van Laethem","year":"2010","unstructured":"Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study. J Clin Oncol. 2010;28(29):4450\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"16408_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1097\/SLA.0b013e318190c53e","volume":"248","author":"MJ Morak","year":"2008","unstructured":"Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, et al. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg. 2008;248(6):1031\u201341.","journal-title":"Ann Surg"},{"issue":"1","key":"16408_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/COC.0000000000000115","volume":"40","author":"MR Khawaja","year":"2017","unstructured":"Khawaja MR, Kleyman S, Yu Z, Howard T, Burns M, Nakeeb A, et al. Adjuvant Gemcitabine and gemcitabine-based chemoradiotherapy versus gemcitabine alone after pancreatic cancer resection: the Indiana University experience. Am J Clin Oncol. 2017;40(1):42\u20136.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"16408_CR24","first-page":"3441","volume":"35","author":"GC Mattiucci","year":"2015","unstructured":"Mattiucci GC, Falconi M, RG VANS, Alfieri S, Calvo FA, Herman JM, et al. Adjuvant chemoradiation in pancreatic cancer: a pooled analysis in elderly (>\/=75 years) patients. Anticancer Res. 2015;35(6):3441\u20136.","journal-title":"Anticancer Res"},{"issue":"3","key":"16408_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/jgo.2018.02.02","volume":"9","author":"WH Jin","year":"2018","unstructured":"Jin WH, Hoffe SE, Shridhar R, Strom T, Venkat P, Springett GM, et al. Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail. J Gastrointest Oncol. 2018;9(3):487\u201394.","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"16408_CR26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","volume":"230","author":"JH Klinkenbijl","year":"1999","unstructured":"Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776\u201382. discussion 782\u2009\u2013\u2009774.","journal-title":"Ann Surg"},{"issue":"33","key":"16408_CR27","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1200\/JCO.2011.38.2960","volume":"30","author":"J Schmidt","year":"2012","unstructured":"Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30(33):4077\u201383.","journal-title":"J Clin Oncol"},{"issue":"8","key":"16408_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023003","volume":"120","author":"MH Kalser","year":"1985","unstructured":"Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899\u2013903.","journal-title":"Arch Surg"},{"key":"16408_CR29","doi-asserted-by":"publisher","first-page":"660215","DOI":"10.3389\/fonc.2021.660215","volume":"11","author":"J Xing","year":"2021","unstructured":"Xing J, Yang B, Hou X, Jia N, Gong X, Li X, et al. Prognostic factors and effect of adjuvant chemoradiation following chemotherapy in resected pancreatic cancer patients with lymph node metastasis or R1 resection. Front Oncol. 2021;11:660215.","journal-title":"Front Oncol"},{"issue":"1","key":"16408_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1186\/s12885-022-09974-7","volume":"22","author":"T Ma","year":"2022","unstructured":"Ma T, Bai X, Wei Q, Shui Y, Lao M, Chen W, et al. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial. BMC Cancer. 2022;22(1):865.","journal-title":"BMC Cancer"},{"issue":"10","key":"16408_CR31","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.21873\/anticanres.15283","volume":"41","author":"F Pasqualetti","year":"2021","unstructured":"Pasqualetti F, Sainato A, Morganti R, Laliscia C, Vasile E, Gonnelli A, et al. Adjuvant radiotherapy in patients with pancreatic adenocarcinoma. is it still appealing in clinical trials? A meta-analysis and review of the literature. Anticancer Res. 2021;41(10):4697\u2013704.","journal-title":"Anticancer Res"},{"issue":"10073","key":"16408_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011\u201324.","journal-title":"Lancet"},{"issue":"29","key":"16408_CR33","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","volume":"35","author":"M Sinn","year":"2017","unstructured":"Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, et al. CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol. 2017;35(29):3330\u20137.","journal-title":"J Clin Oncol"},{"issue":"25","key":"16408_CR34","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med"},{"key":"16408_CR35","doi-asserted-by":"publisher","first-page":"175883592110458","DOI":"10.1177\/17588359211045861","volume":"13","author":"S Iyengar","year":"2021","unstructured":"Iyengar S, Nevala-Plagemann C, Garrido-Laguna I. Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Ther Adv Med Oncol. 2021;13:17588359211045861.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"16408_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.hpb.2019.12.001","volume":"22","author":"SK Kamarajah","year":"2020","unstructured":"Kamarajah SK, Bundred JR, Alrawashdeh W, Manas D, White SA. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC). HPB (Oxford). 2020;22(5):649\u201359.","journal-title":"HPB (Oxford)"},{"issue":"3","key":"16408_CR37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/cam4.1967","volume":"8","author":"SJ Ma","year":"2019","unstructured":"Ma SJ, Hermann GM, Prezzano KM, Serra LM, Iovoli AJ, Singh AK. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer. Cancer Med. 2019;8(3):939\u201352.","journal-title":"Cancer Med"},{"issue":"4","key":"16408_CR38","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jamcollsurg.2015.12.031","volume":"222","author":"AA Parikh","year":"2016","unstructured":"Parikh AA, Maiga A, Bentrem D, Squires MH 3rd, Kooby DA, Maithel SK, et al. Adjuvant therapy in pancreas cancer: does it influence patterns of recurrence? J Am Coll Surg. 2016;222(4):448\u201356.","journal-title":"J Am Coll Surg"},{"issue":"15","key":"16408_CR39","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2217\/fon-2021-0483","volume":"18","author":"BP Venkatesulu","year":"2022","unstructured":"Venkatesulu BP, Chan DP, Giridhar P, Upadhyay R, Sharma A, Elghazawy H, et al. A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in pancreatic cancer. Future Oncol. 2022;18(15):1885\u201395.","journal-title":"Future Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16408-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:39:59Z","timestamp":1789609199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16408-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16408"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16408-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1105"}}